Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Clin Pharmacol ; 63(1): 119-125, 2023 01.
Article in English | MEDLINE | ID: mdl-35996877

ABSTRACT

Venetoclax is an approved, orally bioavailable, B-cell lymphoma type 2 (BCL-2) inhibitor that is primarily metabolized by cytochrome P450 3A (CYP3A). Polypharmacy is common in patients undergoing treatment for hematological malignancies such as acute myeloid leukemia or chronic lymphocytic leukemia, and although venetoclax exposure has been well characterized with 1 concomitant CYP3A inhibitor, complex drug-drug interactions (DDIs) involving more than 1 inhibitor have not been systematically evaluated. Here, we aimed to describe the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics (PK) using physiologically based pharmacokinetic (PBPK) and population PK modeling. The modeling approaches were informed by clinical data in the presence of single or multiple CYP3A inhibitors, and the effects of 1 or more inhibitors were systematically considered within these modeling frameworks. The PBPK modeling approach was independently validated against clinical data involving more than 1 CYP3A inhibitor along with CYP3A substrates other than venetoclax. Both approaches indicated that combining a strong CYP3A inhibitor with another competitive CYP3A inhibitor does not seem to result in any additional increase in venetoclax exposure, beyond what would be expected with a strong inhibitor alone. This suggests that the current dose reductions recommended for venetoclax would be appropriate even when 2 or more CYP3A inhibitors are taken concomitantly. However, the results indicate that the involvement of time-dependent inhibition might lead to additional inhibitory effects over and above the effect of a single strong CYP3A inhibitor. Thus, the clinical management of such interactions must consider the underlying mechanism of the interactions.


Subject(s)
Antineoplastic Agents , Cytochrome P-450 CYP3A Inhibitors , Humans , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Cytochrome P-450 CYP3A/metabolism , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , Sulfonamides/pharmacokinetics , Drug Interactions , Antineoplastic Agents/pharmacokinetics , Models, Biological
2.
Clin Transl Sci ; 14(4): 1431-1443, 2021 07.
Article in English | MEDLINE | ID: mdl-33931953

ABSTRACT

The missense variant, breast cancer resistance protein (BCRP) p.Q141K, which encodes a reduced function BCRP, has been linked to poor response to allopurinol. Using a multifaceted approach, we aimed to characterize the relationship(s) between BCRP p.Q141K, the pharmacokinetics (PK) and pharmacodynamics (PD) of oxypurinol (the active metabolite of allopurinol), and serum uric acid (SUA) levels. A prospective clinical study (NCT02956278) was conducted in which healthy volunteers were given a single oral dose of 300 mg allopurinol followed by intensive blood sampling. Data were analyzed using noncompartmental analysis and population PK/PD modeling. Additionally, electronic health records were analyzed to investigate whether clinical inhibitors of BCRP phenocopied the effects of the p.Q141K variant with respect to SUA. Subjects homozygous for p.Q141K had a longer half-life (34.2 ± 12.2 h vs. 19.1 ± 1.42 h) of oxypurinol. The PK/PD model showed that women had a 24.8% lower volume of distribution. Baseline SUA was affected by p.Q141K genotype and renal function; that is, it changed by 48.8% for every 1 mg/dl difference in serum creatinine. Real-world data analyses showed that patients prescribed clinical inhibitors of BCRP have higher SUA levels than those that have not been prescribed inhibitors of BCRP, consistent with the idea that BCRP inhibitors phenocopy the effects of p.Q141K on uric acid levels. This study identified important covariates of oxypurinol PK/PD that could affect its efficacy for the treatment of gout as well as a potential side effect of BCRP inhibitors on increasing uric acid levels, which has not been described previously.


Subject(s)
ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics , Neoplasm Proteins/genetics , Oxypurinol/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , Adolescent , Adult , Creatinine/blood , Creatinine/metabolism , Female , Glomerular Filtration Rate , Half-Life , Healthy Volunteers , Humans , Male , Middle Aged , Models, Biological , Mutation, Missense , Neoplasm Proteins/metabolism , Oxypurinol/administration & dosage , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Prospective Studies , Renal Elimination , Sex Factors , Uric Acid/blood , Uric Acid/metabolism , Young Adult
3.
PLoS Genet ; 15(8): e1008318, 2019 08.
Article in English | MEDLINE | ID: mdl-31415568

ABSTRACT

Elevated uric acid (UA) is a key risk factor for many disorders, including metabolic syndrome, gout and kidney stones. Despite frequent occurrence of these disorders, the genetic pathways influencing UA metabolism and the association with disease remain poorly understood. In humans, elevated UA levels resulted from the loss of the of the urate oxidase (Uro) gene around 15 million years ago. Therefore, we established a Drosophila melanogaster model with reduced expression of the orthologous Uro gene to study the pathogenesis arising from elevated UA. Reduced Uro expression in Drosophila resulted in elevated UA levels, accumulation of concretions in the excretory system, and shortening of lifespan when reared on diets containing high levels of yeast extract. Furthermore, high levels of dietary purines, but not protein or sugar, were sufficient to produce the same effects of shortened lifespan and concretion formation in the Drosophila model. The insulin-like signaling (ILS) pathway has been shown to respond to changes in nutrient status in several species. We observed that genetic suppression of ILS genes reduced both UA levels and concretion load in flies fed high levels of yeast extract. Further support for the role of the ILS pathway in modulating UA metabolism stems from a human candidate gene study identifying SNPs in the ILS genes AKT2 and FOXO3 being associated with serum UA levels or gout. Additionally, inhibition of the NADPH oxidase (NOX) gene rescued the reduced lifespan and concretion phenotypes in Uro knockdown flies. Thus, components of the ILS pathway and the downstream protein NOX represent potential therapeutic targets for treating UA associated pathologies, including gout and kidney stones, as well as extending human healthspan.


Subject(s)
Gout/etiology , Kidney Calculi/etiology , Metabolic Networks and Pathways/genetics , Signal Transduction/genetics , Uric Acid/metabolism , Animals , Animals, Genetically Modified , Cohort Studies , Disease Models, Animal , Drosophila melanogaster , Feeding Behavior , Female , Gene Knockdown Techniques , Gout/metabolism , Humans , Insulin/metabolism , Kidney Calculi/metabolism , Longevity/genetics , Male , Middle Aged , NADPH Oxidases/genetics , NADPH Oxidases/metabolism , Polymorphism, Single Nucleotide , Purines/administration & dosage , Purines/adverse effects , Urate Oxidase/genetics , Urate Oxidase/metabolism
4.
Clin Pharmacol Ther ; 106(3): 623-631, 2019 09.
Article in English | MEDLINE | ID: mdl-30924126

ABSTRACT

Allopurinol, which lowers uric acid (UA) concentration, is increasingly being recognized for its benefits in cardiovascular and renal disease. However, response to allopurinol is variable. We gathered samples from 4,446 multiethnic subjects for a genome-wide association study of allopurinol response. Consistent with previous studies, we observed that the Q141K variant in ABCG2 (rs2231142), which encodes the efflux pump breast cancer resistance protein (BCRP), associated with worse response to allopurinol. However, for the first time this association reached genome-wide level significance (P = 8.06 × 10-11 ). Additionally, we identified a novel association with a variant in GREM2 (rs1934341, P = 3.22 × 10-6 ). In vitro studies identified oxypurinol, the active metabolite of allopurinol, as an inhibitor of the UA transporter GLUT9, suggesting that oxypurinol may modulate UA reabsorption. These results provide strong evidence for a role of BCRP Q141K in allopurinol response, and suggest that allopurinol may have additional hypouricemic effects beyond xanthine oxidase inhibition.


Subject(s)
ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics , Allopurinol/pharmacology , Neoplasm Proteins/genetics , Uric Acid/metabolism , Aged , Aged, 80 and over , Cytokines/genetics , Ethnicity , Female , Genome-Wide Association Study , Glucose Transport Proteins, Facilitative/antagonists & inhibitors , Humans , Male , Middle Aged , Oxypurinol/pharmacology , Prognosis
5.
Clin Pharmacol Ther ; 104(5): 803-817, 2018 11.
Article in English | MEDLINE | ID: mdl-29679469

ABSTRACT

Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.


Subject(s)
Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Pharmaceutical Preparations/metabolism , Pharmacogenomic Variants , Pharmacokinetics , Polymorphism, Genetic , Animals , Drug Interactions , Drug-Related Side Effects and Adverse Reactions/genetics , Drug-Related Side Effects and Adverse Reactions/metabolism , Genotype , Humans , Phenotype , Risk Assessment
6.
Clin Pharmacol Ther ; 103(2): 233-242, 2018 02.
Article in English | MEDLINE | ID: mdl-29023674

ABSTRACT

Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies.


Subject(s)
ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , Antineoplastic Agents/therapeutic use , Drug Development/methods , Drug Discovery/methods , Evidence-Based Medicine/methods , Neoplasm Proteins/metabolism , Neoplasms/drug therapy , Translational Research, Biomedical/methods , ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics , Animals , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacokinetics , Data Mining , Databases, Factual , Drug Resistance, Neoplasm , Humans , Models, Animal , Models, Theoretical , Neoplasm Proteins/genetics , Neoplasms/genetics , Neoplasms/metabolism , Neoplasms/pathology , Patient Safety , Pharmacogenomic Variants , Risk Assessment
8.
J Antimicrob Chemother ; 69(1): 168-75, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23956375

ABSTRACT

OBJECTIVES: The imidazoquinoline family of drugs are Toll-like receptor 7/8 agonists that have previously been used in the treatment of cutaneous leishmaniasis. Because of the hydrophobic nature of imidazoquinolines, they are traditionally not administered systemically for the treatment of visceral leishmaniasis. We formulated liposomal resiquimod, an imidazoquinoline, for the systemic treatment of visceral leishmaniasis. METHODS: By using lipid film hydration with extrusion, we encapsulated resiquimod in liposomes. These liposomes were then injected intravenously to treat BALB/c mice infected with Leishmania donovani. RESULTS: Treatment with liposomal resiquimod significantly decreased the parasite load in the liver, spleen and bone marrow. In addition, resiquimod treatment increased interferon-γ and interleukin-10 production in an antigen recall assay. Resiquimod was shown to be non-toxic in histology and in vitro culture experiments. CONCLUSIONS: FDA-approved resiquimod, in a liposomal formulation, displays promising results in treating visceral leishmaniasis.


Subject(s)
Antiprotozoal Agents/administration & dosage , Imidazoles/administration & dosage , Leishmania donovani/drug effects , Leishmaniasis, Visceral/drug therapy , Liposomes/administration & dosage , Administration, Intravenous , Animals , Bone Marrow/parasitology , Disease Models, Animal , Interferon-gamma/metabolism , Interleukin-10/metabolism , Leishmania donovani/isolation & purification , Leishmaniasis, Visceral/parasitology , Leukocytes, Mononuclear/immunology , Liver/parasitology , Mice , Mice, Inbred BALB C , Parasite Load , Spleen/parasitology , Treatment Outcome
9.
Langmuir ; 29(25): 7957-65, 2013 Jun 25.
Article in English | MEDLINE | ID: mdl-23725054

ABSTRACT

Electrospun acetalated dextran (Ac-DEX) scaffolds were fabricated to encapsulate resiquimod, an immunomodulatory toll-like-receptor (TLR) agonist. Ac-DEX has been used to fabricate scaffolds for sustained and temporal delivery of therapeutics because it has tunable degradation rates that are dependent on its synthesis reaction time or the molecular weight of dextran. Additionally, as opposed to commonly electrospun polyesters that shift the local pH upon degradation, the degradation products of Ac-DEX are pH-neutral: dextran, an alcohol, and the metabolic byproduct acetone. Formulations of Ac-DEX with two different degradation rates were used in this study. The effects of electrospinning conditions on the scaffold size and morphology were examined as well as fibroblast adhesion as imaged with fluorescence microcopy and scanning electron microscopy. Macrophage (MΦ) viability further indicates that the scaffolds are cytocompatible. Also, the controlled release profiles of resiquimod from loaded scaffolds and nitric oxide (NO) production by MΦ incubated with these scaffolds show the potential for Ac-DEX scaffolds to be used to temporally and efficiently deliver therapeutics. Overall, we present a novel scaffold that can have tunable and unique drug release rates for tissue engineering, drug delivery, immunomodulation, and wound healing applications.


Subject(s)
Dextrans/chemistry , Tissue Scaffolds/chemistry , Animals , Cell Survival , Imidazoles/chemistry , Mice , Microscopy, Electron, Scanning , NIH 3T3 Cells , Nitric Oxide/metabolism
10.
Mol Pharm ; 10(8): 2849-57, 2013 Aug 05.
Article in English | MEDLINE | ID: mdl-23768126

ABSTRACT

To enhance the immune activity of vaccine adjuvants polyinosinic:polycytidylic acid (poly I:C) and CpG acetalated dextran (Ac-DEX) microparticles can be used. Ac-DEX is a biodegradable and water-insoluble polymer that degrades significantly faster at pH 5.0 (phagosomal pH) than at pH 7.4 and has tunable degradation rates that can range from hours to months. This is an ideal characteristic for delivery of an antigen and adjuvant within the lysosomal compartment of a phagocytic cell. We evaluated poly I:C and CpG encapsulated in Ac-DEX microparticles using RAW macrophages as a model antigen-presenting cell. These cells were cultured with poly I:C or CpG in their free form, encapsulated in a fast degrading Ac-DEX, in slow degrading Ac-DEX, or in the Food and Drug Administration-approved polymer poly(lactic-co-glycolic acid) (PLGA). Ac-DEX had higher encapsulation efficiencies for both poly I:C and CpG than PLGA. Furthermore, poly I:C or CpG encapsulated in Ac-DEX also showed, in general, a significantly stronger immunostimulatory response than PLGA and unencapsulated CpG or poly I:C, which was indicated by a higher rate of nitric oxide release and increased levels of cytokines such as TNF-α, IL-6, IL-10, and IFN-γ. Overall, we have illustrated a method for enhancing the delivery of these vaccine adjuvants to further enhance the development of Ac-DEX vaccine formulations.


Subject(s)
Dinucleoside Phosphates/metabolism , Poly I-C/metabolism , Toll-Like Receptors/agonists , Animals , Cell Line , Dextrans/chemistry , Macrophages/drug effects , Macrophages/metabolism , Mice , Microscopy, Atomic Force
SELECTION OF CITATIONS
SEARCH DETAIL
...